Clinical trial · Interventional
HEME Home Transfusion Program
Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial
NCT06487247CI-TRIAL-00095323recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Diseases | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HEME-Hospice Program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1: Access to home blood transfusions while enrolled in hospice (HEME-Hospice care)
- description
- Participants assigned to access to HEME-Hospice care who enroll in hospice will have at least once weekly assessment of symptoms of anemia and thrombocytopenia by the study team and will receive transfusions at home as indicated. Individualized care appointments with hospice care team providers, and frequency of visits are determined by individual participant need.
- interventionNames
- Behavioral: HEME-Hospice Program
- type
- NO_INTERVENTION
- label
- Arm 2: Usual Care
- description
- Participants assigned to usual care will receive standard oncology care delivered by the hematologic oncologists. Participants will have access to regular/standard hospice care if they elect to enroll in hospice.
Primary outcomes (2)
- measure
- Hospice Enrollment Rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria for Patient Participants: * Diagnosis of a relapsed/refractory hematologic malignancy * Age ≥ 18 years * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment) * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction * Patient resides within catchment served by Care Dimensions Hospice * Physician-estimated prognosis of six months or less Inclusion Criteria for Caregivers: * Identified informal caregiver of enrolled patient with hematologic malignancy * Age ≥ 18 years Exclusion Criteria for Patient Participants: * Age \< 18 years * Already enrolled in hospice * Resides in nursing home or assisted living facility * History of previous serious adverse transfusion reaction Exclusion Criteria for Caregivers: -Age \< 18 years
References
Publications (0)
Data not yet available
No reference posted for this study.